Roivant Sciences
Tracked across 3 events · 52 articles · First seen May 23, 2025 · Last active Jul 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Roivant Sciences announced the expansion of its brepocitinib program and the failure of Immunovant's batoclimab Phase 3 studies, which could negatively impact its stock.
Apr 02, 2026 · 16 articles
Domestic
Impact: Roivant Sciences, a subsidiary of Roivant Sciences, settled with Moderna for $2.2 billion over unauthorized use of its patents in COVID vaccines.
May 02, 2026 · 30 articles
Business
Impact: Dr. Lynn Seely previously served as president, CEO, and board member of Roivant Sciences Inc., where she commercialized innovative therapies.
Apr 20, 2026 · 6 articles
Organon & Co.
none
↔
Roivant Sciences
Roivant Sciences does not have a direct business-to-business relationship with O
Organon & Co.
none
↔
Roivant Sciences
Organon & Co. does not have a direct business-to-business relationship with Roiv
ERGEN INTELLIGENCE
Track Roivant Sciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard